Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension

Hypertension Research

Volumn 29, Issue 2, 2006, Pages 123-128

  Aizawa, Kazunori ^a   Hanaoka, Takeshi ^a   Kasai, Hiroki ^a   Kogashi, Kaoru ^a   Kumazaki, Setsuo ^a   Koyama, Jun ^a   Tsutsui, Hiroshi ^a   Yazaki, Yoshikazu ^a   Watanabe, Noboru ^a   Kinoshita, Osamu ^a   Ikeda, Uichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brain natriuretic peptide; Phosphodiesterase 5 inhibitor; Pulmonary hypertension; Vardenafil; Vascular resistance

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; VARDENAFIL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; EISENMENGER COMPLEX; FEMALE; FLUSHING; FOLLOW UP; HEART FAILURE; HEART HEMODYNAMICS; HEART OUTPUT; HEART SURGERY; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPOTENSION; LIVER TOXICITY; LONG TERM CARE; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MAINTENANCE THERAPY; MALE; PILOT STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; IMIDAZOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 33645761134     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.123     Document Type: Article

References (31)

1. Archer S, Rich S: Primary pulmonary hypertension: A vascular biology and translational research "work in progress." Circulation 2000; 102: 2781-2791.
2. Newman JH: Treatment of primary pulmonary hypertension - the next generation. N Engl J Med 2002; 346: 933-934.
3. Ghofrani RA, Wiedemann R, Rose F, et al: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial. Lancet 2002; 360: 995-900.
4. Beavo JA: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-748.
5. Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ: Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 1991; 308: 191-197.
6. Lepore JJ, Maroo A, Pereira NL, et al: Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with pulmonary hypertension. Am J Cardiol 2002; 90: 677-680.
7. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-2403.
8. Cheitlin MD, Hutter AM Jr, Brindis RG, et al: Use of sildenafil (viagra) in patients with cardiovascular disease. Circulation 1999; 99: 168-177.
9. Zhao L, Mason NA, Morrell NW, et al: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: 424-428.
10. Shekerdernian LS, Ravn HB, Penny DJ: Intravenous sildenafil lowes pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002; 165: 1098-1102.
11. Kataoka M, Satoh T, Manabe T, et al: Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 2005; 69: 461-465.
12. Abrams D, Schulze-Neick I, Magee AG: Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4.
13. Michelakis ED, Tymchak W, Noga M, et al: Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-2069.
14. Watanabe H, Ohashi K, Takeuchi K, et al: Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 2002; 71: 398-402.
15. Corbin JD, Beasley A, Blount MA, Francis SH: Vardenafil: Structural basis for higher potency over sildenafil in inhibit- ing cGMP-specific phoshodiesterase-5 (PDE5). Neurochem Int 2004;45:859-863.
16. Ghofrani HA, Voswinckel R, Reichenberger F, et al: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2004; 44: 1488-1496.
17. Saenz de Tejada I, Angulo J, Cuevas P, et al: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282-290.
18. Ikeda D, Tsujino I, Ohira H, et al: Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. J Cardiovas Pharmacol 2005; 45: 286-289.
19. Prasad S, Wilkinson J, Gatzoulis MA: Sildenafil in primary pulmonary hypertension letter. N Engl J Med 2000; 343: 1342.
20. Wharton J, Strange JW, Moller GM, et al: Anti-proliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Care Med 2005; 172: 105-113.
21. Heinrike W, Angelika G, Jochem K, et al: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-1222.
22. Imanishi T, Hano T, Nishio I: Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens Res 2004; 27: 101-108.
23. Foresta C, Lana A, Cabrelle A, et al: PDE-5 inhibitor, vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 2005; 17: 377-380.
24. Nagaya N, Nishikimi T, Uematsu M, et al: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
25. Anan F, Takahashi N, Ooie T, Yufu K, Saikawa T, Yoshimatsu H: Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res 2003; 26: 669-676.
26. Kato J, Kitamura K, Uenmra T, et al: Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: Their relations to age and pulse pressure. Hypertens Res 2002; 25: 887-892.
27. Yambe M, Tomita H, Hirayama Y, et al: Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure. Hypertens Res 2004; 27: 625-632.
28. Ogata C, Horio T, Kamide K, Takiuchi S, Kawano Y: Association between left ventricular diastolic dysfunction and renal hemodynamic change in patients with treated essential hypertension. Hypertens Res 2003; 26: 971-978.
29. Takahashi N, Saito Y, Kuwahara K, et al: Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation. Hypertens Res 2003; 26: 847-853.
30. Eric R, Evangelos DM, Wayne T, et al: Sildenafil use in patients with the Eiserimenger syndrome. Circulation 2004; 109: 197.
31. Marius MH, Roman M, Joern T, et al: Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 535-541.